The Stryker (NYQ:SYK) share price has risen by 5.01% over the past month and it’s currently trading at 233.01. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue....
SYK — Stryker Share Price
- $88.84bn
- $101.41bn
- $17.11bn
- 95
- 24
- 86
- 76
Momentum
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 23.24 | ||
PEG Ratio (f) | 1.16 | ||
EPS Growth (f) | 24.99% | ||
Dividend Yield (f) | 1.23% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 5.91 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 36.23 | ||
Price to Sales | 5.1 | ||
EV to EBITDA | 28.81 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 8.08% | ||
Return on Equity | 14.12% | ||
Operating Margin | 14.72% |
Financial Summary
Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 12,444 | 13,601 | 14,884 | 14,351 | 17,108 | 18,432.47 | 19,743.06 | 8.6% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +13.75 | +80.29 | -35.82 | -10.96 | +14.45 | +36.61 | +12.24 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Latest News & Insights for SYK
The Stryker (NYQ:SYK) share price has risen by 5.14% over the past month and it’s currently trading at 197.62. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue....
The Stryker (NYQ:SYK) share price has risen by 6.21% over the past month and it’s currently trading at 189.56. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue....
The Stryker (NYQ:SYK) share price has risen by 6.21% over the past month and it’s currently trading at 189.56. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run will continue....
In this article we will quickly re-cap the broker forecasts for Stryker (NYQ:SYK). The Stryker share price has risen by 9.21% over the past month and it’s currently trading at 198.39. For investors considering whether to buy, hold or s...
Profile Summary
Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopaedics, and Spine that help improve patient and hospital outcomes. Its products are sold in approximately 75 countries through Company-owned subsidiaries and branches, as well as, third-party dealers and distributors. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a range of medical specialties. Its business segments include MedSurg and Neurotechnology and Orthopaedics and Spine. Its subsidiaries include Alcott Indemnity Company, Arrinex, Inc., Berchtold Corporation, and BioMimetic Therapeutics, LLC.
Directors
- Kevin Lobo CHM (56)
- Glenn Boehnlein CFO (59)
- Viju Menon CEX (53)
- M. Kathryn Fink CHO (51)
- William Berry CAO (55)
- Yin Becker VPR (57)
- Robert Fletcher VPR (50)
- Allan Golston LED (54)
- Mary Brainerd IND (67)
- Giovanni Caforio IND (56)
- Srikant Datar IND (68)
- Sherilyn McCoy IND (62)
- Andrew Silvernail IND (50)
- Lisa Skeete Tatum IND (53)
- Ronda Stryker IND (66)
- Rajeev Suri IND (53)
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- February 20th, 1946
- Public Since
- July 24th, 1997
- No. of Shareholders
- 2,543
- No. of Employees
- 46,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange
- Shares in Issue
- 378,154,080

- Address
- 2825 Airview Blvd, KALAMAZOO, 49002
- Web
- https://www.stryker.com/
- Phone
- +1 2693892600
- Auditors
- Ernst & Young LLP
Latest News for SYK
Upcoming Events for SYK
Dividend For S1YK34.SA - 0.8704 BRL
Dividend For SYK.N - 0.6950 USD
Q2 2022 Stryker Corp Earnings Release
Q3 2022 Stryker Corp Earnings Release
Similar to SYK
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
AmerisourceBergen
New York Stock Exchange
FAQ
As of Today at 19:21 UTC, shares in Stryker are trading at $235.01. This share price information is delayed by 15 minutes.
Shares in Stryker last closed at $235.01 and the price had moved by -8.48% over the past 365 days. In terms of relative price strength the Stryker share price has underperformed the S&P500 Index by -3.48% over the past year.
The overall consensus recommendation for Stryker is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Stryker dividend yield is 1.13% based on the trailing twelve month period.
Last year, Stryker paid a total dividend of $2.65, and it currently has a trailing dividend yield of 1.13%. We do not have any data on when Stryker is to next pay dividends.
We do not have data on when Stryker is to next pay dividends. The historic dividend yield on Stryker shares is currently 1.13%.
To buy shares in Stryker you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $235.01, shares in Stryker had a market capitalisation of $88.84bn.
Here are the trading details for Stryker:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: SYK
Based on an overall assessment of its quality, value and momentum Stryker is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Stryker is $283.08. That is 20.46% above the last closing price of $235.01.
Analysts covering Stryker currently have a consensus Earnings Per Share (EPS) forecast of $9.64 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stryker. Over the past six months, its share price has outperformed the S&P500 Index by +12.93%.
As of the last closing price of $235.01, shares in Stryker were trading -9.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Stryker PE ratio based on its reported earnings over the past 12 months is 23.24. The shares last closed at $235.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Stryker's management team is headed by:
- Kevin Lobo - CHM
- Glenn Boehnlein - CFO
- Viju Menon - CEX
- M. Kathryn Fink - CHO
- William Berry - CAO
- Yin Becker - VPR
- Robert Fletcher - VPR
- Allan Golston - LED
- Mary Brainerd - IND
- Giovanni Caforio - IND
- Srikant Datar - IND
- Sherilyn McCoy - IND
- Andrew Silvernail - IND
- Lisa Skeete Tatum - IND
- Ronda Stryker - IND
- Rajeev Suri - IND